Medical Costs of Persons with Drug Use Disorders Among Medicaid Managed Care Beneficiaries in Puerto Rico
| Autor: | Heriberto A. Marín Centeno, Carmen E. Albizu-García, José E. Laborde Rivera, Héctor Colón Jordán |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Male
medicine.medical_specialty Health (social science) Substance-Related Disorders Beneficiary Health informatics 03 medical and health sciences 0302 clinical medicine Environmental health Health care Humans Medicine 030212 general & internal medicine Drug Use Disorders health care economics and organizations Service (business) Medicaid managed care Medicaid business.industry 030503 health policy & services Health Policy Public health Managed Care Programs Puerto Rico Public Health Environmental and Occupational Health Health Care Costs United States Health psychology Female 0305 other medical science business |
| Zdroj: | The Journal of Behavioral Health Services & Research. 43:293-304 |
| ISSN: | 1556-3308 1094-3412 |
| DOI: | 10.1007/s11414-015-9469-4 |
| Popis: | Drug use disorders (DUDs) can substantially increase the costs of health care, especially when left untreated. Yet, not much is known about the specific types of medical services that give rise to these cost differences. This study aimed to estimate the medical costs of beneficiaries with DUDs enrolled in the Medicaid Managed Care (MMC) program in Puerto Rico using claims data. These were compared to those of a matched group of patients without DUDs. On average, each beneficiary with a DUD incurred in $4539 annually on medical services compared to $2601 in the matched comparison group, a cost differential of $1938. Close to half of these additional medical costs (43.4%) were generated in the physical health services sector. Counts of service claims were also higher for beneficiaries with DUDs than for beneficiaries without DUDs in all service types, except in outpatient and laboratory services for physical health. A host of access strategies and treatment modalities should be tested to assess the extent to which providing adequate access and adequate treatment for a DUD can contribute to cost savings. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink